Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases Deep Apple is eligible to receive up to $812 million, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback